Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

The interrelationships between Src, Cav-1 and RhoGD12 in transitional cell carcinoma of the bladder.

Qayyum T, Fyffe G, Duncan M, McArdle PA, Hilmy M, Orange C, Halbert G, Seywright M, Horgan PG, Underwood MA, Edwards J.

Br J Cancer. 2012 Mar 13;106(6):1187-95. doi: 10.1038/bjc.2012.52. Epub 2012 Feb 21.

2.

Expression and prognostic significance of Src family members in renal clear cell carcinoma.

Qayyum T, McArdle PA, Lamb GW, Jordan F, Orange C, Seywright M, Horgan PG, Jones RJ, Oades G, Aitchison MA, Edwards J.

Br J Cancer. 2012 Aug 21;107(5):856-63. doi: 10.1038/bjc.2012.314. Epub 2012 Jul 19.

3.

Pathways of metastasis suppression in bladder cancer.

Said N, Theodorescu D.

Cancer Metastasis Rev. 2009 Dec;28(3-4):327-33. doi: 10.1007/s10555-009-9197-4. Review.

PMID:
20013033
4.

Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer.

Thomas S, Overdevest JB, Nitz MD, Williams PD, Owens CR, Sanchez-Carbayo M, Frierson HF, Schwartz MA, Theodorescu D.

Cancer Res. 2011 Feb 1;71(3):832-41. doi: 10.1158/0008-5472.CAN-10-0730. Epub 2010 Dec 10.

5.

Deciphering mechanisms controlling placental artery endothelial cell migration stimulated by vascular endothelial growth factor.

Liao WX, Feng L, Zheng J, Chen DB.

Endocrinology. 2010 Jul;151(7):3432-44. doi: 10.1210/en.2009-1305. Epub 2010 May 12.

6.
7.

Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function.

Wu Y, Moissoglu K, Wang H, Wang X, Frierson HF, Schwartz MA, Theodorescu D.

Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5807-12. doi: 10.1073/pnas.0810094106. Epub 2009 Mar 25.

9.

[Analysis of the relationship between expression of caveolin-1 and prognosis in bladder transitional cell carcinoma].

Ruan J, Weng ZL.

Zhonghua Zhong Liu Za Zhi. 2010 Jun;32(6):429-31. Chinese.

PMID:
20819483
10.

WAF1/p21 protein expression is an independent prognostic indicator in superficial and invasive bladder cancer.

Korkolopoulou P, Konstantinidou AE, Thomas-Tsagli E, Christodoulou P, Kapralos P, Davaris P.

Appl Immunohistochem Mol Morphol. 2000 Dec;8(4):285-92.

PMID:
11127920
11.

FAK and Src expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival.

Theocharis S, Klijanienko J, Giaginis C, Alexandrou P, Patsouris E, Sastre-Garau X.

J Cancer Res Clin Oncol. 2012 Aug;138(8):1369-77. doi: 10.1007/s00432-012-1215-1. Epub 2012 Apr 10.

PMID:
22488171
12.

Quantification of focal adhesion kinase activation loop phosphorylation as a biomarker of Src activity.

Ciccimaro E, Hanks SK, Blair IA.

Mol Pharmacol. 2009 Mar;75(3):658-66. doi: 10.1124/mol.108.052464. Epub 2008 Dec 19.

13.

Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.

Sun CH, Chang YH, Pan CC.

Histopathology. 2011 Jun;58(7):1054-63. doi: 10.1111/j.1365-2559.2011.03856.x.

PMID:
21707707
14.

PFKFB4 as a prognostic marker in non-muscle-invasive bladder cancer.

Yun SJ, Jo SW, Ha YS, Lee OJ, Kim WT, Kim YJ, Lee SC, Kim WJ.

Urol Oncol. 2012 Nov-Dec;30(6):893-9. doi: 10.1016/j.urolonc.2010.08.018. Epub 2011 Mar 10.

PMID:
21396842
15.
17.

CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma.

Xue Y, Wu G, Wang X, Zou X, Zhang G, Xiao R, Yuan Y, Long D, Yang J, Wu Y, Xu H, Liu F, Liu M.

Med Oncol. 2013 Mar;30(1):406. doi: 10.1007/s12032-012-0406-6. Epub 2012 Dec 30.

PMID:
23275123
18.

Evidence for in vivo phosphorylation of the Grb2 SH2-domain binding site on focal adhesion kinase by Src-family protein-tyrosine kinases.

Schlaepfer DD, Hunter T.

Mol Cell Biol. 1996 Oct;16(10):5623-33. Erratum in: Mol Cell Biol 1996 Dec;16(12):7182-4.

20.

Supplemental Content

Support Center